42 terminated. 42 Phase 2, 9 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 42 | Terminated 42 |
| Phase 1 | 9 | Terminated 9 |
| Phase 3 | 4 | Terminated 4 |
Follow Hepatitis C: new trials by email Literature Review of Hepatitis C trials Research Report on Hepatitis C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis Ambrisentan - Cirrhosis, Portal Hypertension | Phase 2 | Terminated | Noorik Biopharmaceuticals AG | 19 | 2019-04-11 | 2021-02-26 |
| Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection SOF/VEL/VOX - Hepatitis C Virus Infection | Phase 2 | Terminated | Gilead Sciences | 21 | 2019-01-28 | 2020-10-23 |
| Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection Daclatasvir, Sofosbuvir - Hepatitis C, Chronic Hepatitis | Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2018-06-25 | 2021-04-20 |
| Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C 20mg ezetimibe, Placebo, 40mg ezetimibe - Chronic Hepatitis C | Phase 2 | Terminated | VA Office of Research and Development | 2 | 2018-04-16 | 2022-06-06 |
| Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041) Uprifosbuvir, Ruzasvir, Ribavirin - Hepatitis C | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 282 | 2016-11-16 | 2021-02-02 |
| Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035) Uprifosbuvir 450 mg, Ruzasvir 60 mg - Hepatitis C, Chronic | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 160 | 2016-05-03 | 2019-06-26 |
| 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF Ledipasvir/sofosbuvir, Ribavirin - HIV-1 Infection, Hepatitis C | Phase 2 | Terminated | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 7 | 2016-02-17 | 2018-05-02 |
| Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) MK-3682B, Ribavirin - Hepatitis, Hepatitis C | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 94 | 2015-12-10 | 2024-05-22 |
| Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV) - HIV Infections, Hepatitis C | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 46 | 2015-09-16 | 2021-11-04 |
| Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies JKB-122 5mg, JKB-122 15mg, JKB-122 35mg - Chronic Hepatitis C | Phase 2 | Terminated | TaiwanJ Pharmaceuticals Co., Ltd | 54 | 2014-05-01 | 2020-07-21 |
| A Health Intervention to Prevent Depression Hepatitis C Patients Exercise, Health Education - Hepatitis C, Major Depressive Disorder | Phase 2 / Phase 3 | Terminated | University of Texas Southwestern Medical Center | 1 | 2013-06-01 | 2016-12-29 |
| Interaction Between Paroxetine and Telaprevir Paroxetine, telaprevir - Hepatitis C Infection, Depression | Phase 2 | Terminated | Radboud University Medical Center | 3 | 2013-05-01 | 2020-12-08 |
| Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C Ribavirin, Hydroxychloroquine - Hepatitis C | Phase 1 / Phase 2 | Terminated | BioLineRx, Ltd. | 4 | 2013-04-01 | 2014-08-28 |
| Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C Eltrombopag - Thrombocytopenia, Hepatitis C | Phase 2 / Phase 3 | Terminated | University of Texas Southwestern Medical Center | 7 | 2013-04-01 | 2019-11-13 |
| An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus Telaprevir, Peginterferon alfa-2b, Ribavirin - Hepatitis C | Phase 1 / Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 42 | 2013-01-01 | 2016-07-20 |
| Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2) - Hepatitis C Infection | Phase 2 | Terminated | MassBiologics | 11 | 2012-11-21 | 2021-02-05 |
| Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients implantation - Hepatitis C | Phase 1 / Phase 2 | Terminated | Medgenics Medical Israel Ltd. | 3 | 2012-10-01 | 2016-09-13 |
| Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a - Hepatitis C | Phase 2 | Terminated | Bristol-Myers Squibb | 210 | 2012-05-01 | 2015-11-04 |
| An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a - Hepatitis C | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 61 | 2012-02-01 | 2015-06-18 |
| Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012) Grazoprevir, Placebo to Grazoprevir, Peginterferon alfa-2b (Peg-IFN) - Hepatitis C, Chronic | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 5 | 2011-11-28 | 2024-05-22 |
Showing 20 of 42. Sign in to see all of them.
Hepatitis C, Chronic (13) · Hepatitis (5) · Liver Diseases (3) · Depression (2) · HIV Infections (2) · Hepatitis B (2) · Hepatitis, Chronic (2) · Thrombocytopenia (2) · Virus Diseases (2) · Ascites (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Depressive Disorder, Major (1)
Blood-Borne Infections (42) · Communicable Diseases (42) · Infections (42) · Digestive System Diseases (41) · Flaviviridae Infections (41) · Hepatitis, Viral, Human (41) · RNA Virus Infections (41) · Virus Diseases (40) · Liver Diseases (39) · Hepatitis (37) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Disease Attributes (16) · Chronic Disease (15) · Hepatitis, Chronic (13)
Ribavirin (13) · peginterferon alfa-2a (4) · peginterferon alfa-2b (4) · telaprevir (4) · Sofosbuvir (2) · daclatasvir (2) · ruzasvir (2) · uprifosbuvir (2) · BMS-986094 (1) · Blood Specimen Collection (1) · Colchicine (1) · Drug Implants (1) · Everolimus (1) · Exercise (1) · Ezetimibe (1)
Merck Sharp & Dohme LLC (5) · Gilead Sciences (3) · Bristol-Myers Squibb (2) · MassBiologics (2) · Novartis Pharmaceuticals (2) · University of Texas Southwestern Medical Center (2) · Vertex Pharmaceuticals Incorporated (2) · ADMA Biologics, Inc. (1) · ANRS, Emerging Infectious Diseases (1) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Alexion Pharmaceuticals, Inc. (1) · Anza Therapeutics, Inc. (1) · Arrow Therapeutics (1) · Bausch Health Americas, Inc. (1) · BioLineRx, Ltd. (1)
United States (19) · Spain (4) · United Kingdom (4) · Canada (3) · Germany (3) · New Zealand (3) · Taiwan (3) · Australia (2) · France (2) · Israel (2) · Italy (2) · Netherlands (2) · Poland (2) · Puerto Rico (2) · Argentina (1)
Annie Luetkemeyer, MD (1) · Brian Sanderson (1) · Bruno Fallisard, MD (1) · Chad D Rethorst, Ph.D. (1) · Chia-Yen Dai, M.D., M.S. (1) · David Burger, PharmD, PhD (1) · David Mutimer (1) · Deborah C. Molrine, MD (1) · Didier Samuel, MD (1) · Doug Dieterich, MD (1)
PMID 31108015, PMID 19833404, PMID 23356386, PMID 27219495, PMID 27788579, PMID 28688129, PMID 29091342, PMID 30739366, PMID 32406487
2018 (2), 2015 (1), 2016 (1), 2017 (1), UM1AI068636 (1)